Despite pricing pressures and other challenges in the implantable cardioverter defibrillator (ICD) device arena, evidence – along with caution – continues to gather on the benefits of the evolving products to an expanding patient population. (See Also see "Medical Device Market & Industry Briefs, October 2012" - Medtech Insight, 25 October, 2012..)
According to a study by the Duke Clinical Research Institute published January 2 in the Journal of the American Medical Association, patients who received an ICD in everyday practice had...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?